Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Allergan PLC, solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Allergan PLC debt to equity ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Allergan PLC debt to equity ratio (including operating lease liability) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Allergan PLC debt to capital ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Allergan PLC debt to capital ratio (including operating lease liability) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Allergan PLC debt to assets ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Allergan PLC debt to assets ratio (including operating lease liability) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Allergan PLC financial leverage ratio increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Allergan PLC interest coverage ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |
Debt to Equity
Allergan PLC, debt to equity calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current portion of long-term debt | 1,950,700) | 4,532,500) | 3,739,200) | 3,094,200) | 3,971,800) | 868,300) | 1,351,600) | 1,348,500) | 626,200) | 4,231,800) | 3,797,000) | 3,795,000) | 5,526,400) | 2,797,900) | 1,591,800) | 2,506,600) | 4,015,700) | 2,432,800) | 2,035,400) | 1,550,900) | 1,624,100) | |||||||
| Long-term debt, excluding current portion | 17,599,000) | 18,116,500) | 18,786,000) | 19,609,300) | 19,554,100) | 22,929,400) | 22,231,800) | 24,002,000) | 25,936,400) | 25,843,500) | 26,539,100) | 26,443,300) | 26,223,000) | 29,970,800) | 31,178,200) | 37,075,100) | 38,551,800) | 40,293,400) | 40,648,100) | 41,319,400) | 42,700,500) | |||||||
| Total debt | 19,549,700) | 22,649,000) | 22,525,200) | 22,703,500) | 23,525,900) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | 76,591,400) | 77,473,700) | 72,069,100) | 71,404,800) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to equity1 | 0.34 | 0.39 | 0.39 | 0.38 | 0.38 | 0.37 | 0.33 | 0.36 | 0.37 | 0.41 | 0.43 | 0.40 | 0.42 | 0.43 | 0.37 | 0.52 | 0.55 | 0.56 | 0.55 | 0.59 | 0.62 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 3.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 5.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 0.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 19,549,700 ÷ 57,997,700 = 0.34
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Allergan PLC debt to equity ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
Debt to Equity (including Operating Lease Liability)
Allergan PLC, debt to equity (including operating lease liability) calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current portion of long-term debt | 1,950,700) | 4,532,500) | 3,739,200) | 3,094,200) | 3,971,800) | 868,300) | 1,351,600) | 1,348,500) | 626,200) | 4,231,800) | 3,797,000) | 3,795,000) | 5,526,400) | 2,797,900) | 1,591,800) | 2,506,600) | 4,015,700) | 2,432,800) | 2,035,400) | 1,550,900) | 1,624,100) | |||||||
| Long-term debt, excluding current portion | 17,599,000) | 18,116,500) | 18,786,000) | 19,609,300) | 19,554,100) | 22,929,400) | 22,231,800) | 24,002,000) | 25,936,400) | 25,843,500) | 26,539,100) | 26,443,300) | 26,223,000) | 29,970,800) | 31,178,200) | 37,075,100) | 38,551,800) | 40,293,400) | 40,648,100) | 41,319,400) | 42,700,500) | |||||||
| Total debt | 19,549,700) | 22,649,000) | 22,525,200) | 22,703,500) | 23,525,900) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Current portion of lease liability, operating | 119,800) | 124,400) | 118,400) | 123,200) | 116,100) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Lease liability, operating, excluding current portion | 438,300) | 446,100) | 437,400) | 414,800) | 415,200) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 20,107,800) | 23,219,500) | 23,081,000) | 23,241,500) | 24,057,200) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | 76,591,400) | 77,473,700) | 72,069,100) | 71,404,800) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | 0.35 | 0.40 | 0.39 | 0.39 | 0.39 | 0.37 | 0.33 | 0.36 | 0.37 | 0.41 | 0.43 | 0.40 | 0.42 | 0.43 | 0.37 | 0.52 | 0.55 | 0.56 | 0.55 | 0.59 | 0.62 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | 0.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= 20,107,800 ÷ 57,997,700 = 0.35
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Allergan PLC debt to equity ratio (including operating lease liability) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
Debt to Capital
Allergan PLC, debt to capital calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current portion of long-term debt | 1,950,700) | 4,532,500) | 3,739,200) | 3,094,200) | 3,971,800) | 868,300) | 1,351,600) | 1,348,500) | 626,200) | 4,231,800) | 3,797,000) | 3,795,000) | 5,526,400) | 2,797,900) | 1,591,800) | 2,506,600) | 4,015,700) | 2,432,800) | 2,035,400) | 1,550,900) | 1,624,100) | |||||||
| Long-term debt, excluding current portion | 17,599,000) | 18,116,500) | 18,786,000) | 19,609,300) | 19,554,100) | 22,929,400) | 22,231,800) | 24,002,000) | 25,936,400) | 25,843,500) | 26,539,100) | 26,443,300) | 26,223,000) | 29,970,800) | 31,178,200) | 37,075,100) | 38,551,800) | 40,293,400) | 40,648,100) | 41,319,400) | 42,700,500) | |||||||
| Total debt | 19,549,700) | 22,649,000) | 22,525,200) | 22,703,500) | 23,525,900) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | 76,591,400) | 77,473,700) | 72,069,100) | 71,404,800) | |||||||
| Total capital | 77,547,400) | 80,822,600) | 81,000,400) | 82,378,200) | 85,067,900) | 88,911,800) | 94,091,200) | 96,594,000) | 98,890,500) | 103,896,400) | 101,495,500) | 105,458,700) | 106,937,800) | 108,961,400) | 122,495,900) | 116,225,600) | 120,017,500) | 119,317,600) | 120,157,200) | 114,939,400) | 115,729,400) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to capital1 | 0.25 | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | 0.25 | 0.26 | 0.27 | 0.29 | 0.30 | 0.29 | 0.30 | 0.30 | 0.27 | 0.34 | 0.35 | 0.36 | 0.36 | 0.37 | 0.38 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 1.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.46 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 0.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= 19,549,700 ÷ 77,547,400 = 0.25
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Allergan PLC debt to capital ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
Debt to Capital (including Operating Lease Liability)
Allergan PLC, debt to capital (including operating lease liability) calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current portion of long-term debt | 1,950,700) | 4,532,500) | 3,739,200) | 3,094,200) | 3,971,800) | 868,300) | 1,351,600) | 1,348,500) | 626,200) | 4,231,800) | 3,797,000) | 3,795,000) | 5,526,400) | 2,797,900) | 1,591,800) | 2,506,600) | 4,015,700) | 2,432,800) | 2,035,400) | 1,550,900) | 1,624,100) | |||||||
| Long-term debt, excluding current portion | 17,599,000) | 18,116,500) | 18,786,000) | 19,609,300) | 19,554,100) | 22,929,400) | 22,231,800) | 24,002,000) | 25,936,400) | 25,843,500) | 26,539,100) | 26,443,300) | 26,223,000) | 29,970,800) | 31,178,200) | 37,075,100) | 38,551,800) | 40,293,400) | 40,648,100) | 41,319,400) | 42,700,500) | |||||||
| Total debt | 19,549,700) | 22,649,000) | 22,525,200) | 22,703,500) | 23,525,900) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Current portion of lease liability, operating | 119,800) | 124,400) | 118,400) | 123,200) | 116,100) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Lease liability, operating, excluding current portion | 438,300) | 446,100) | 437,400) | 414,800) | 415,200) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 20,107,800) | 23,219,500) | 23,081,000) | 23,241,500) | 24,057,200) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | 76,591,400) | 77,473,700) | 72,069,100) | 71,404,800) | |||||||
| Total capital (including operating lease liability) | 78,105,500) | 81,393,100) | 81,556,200) | 82,916,200) | 85,599,200) | 88,911,800) | 94,091,200) | 96,594,000) | 98,890,500) | 103,896,400) | 101,495,500) | 105,458,700) | 106,937,800) | 108,961,400) | 122,495,900) | 116,225,600) | 120,017,500) | 119,317,600) | 120,157,200) | 114,939,400) | 115,729,400) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | 0.26 | 0.29 | 0.28 | 0.28 | 0.28 | 0.27 | 0.25 | 0.26 | 0.27 | 0.29 | 0.30 | 0.29 | 0.30 | 0.30 | 0.27 | 0.34 | 0.35 | 0.36 | 0.36 | 0.37 | 0.38 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | 0.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 20,107,800 ÷ 78,105,500 = 0.26
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Allergan PLC debt to capital ratio (including operating lease liability) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
Debt to Assets
Allergan PLC, debt to assets calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current portion of long-term debt | 1,950,700) | 4,532,500) | 3,739,200) | 3,094,200) | 3,971,800) | 868,300) | 1,351,600) | 1,348,500) | 626,200) | 4,231,800) | 3,797,000) | 3,795,000) | 5,526,400) | 2,797,900) | 1,591,800) | 2,506,600) | 4,015,700) | 2,432,800) | 2,035,400) | 1,550,900) | 1,624,100) | |||||||
| Long-term debt, excluding current portion | 17,599,000) | 18,116,500) | 18,786,000) | 19,609,300) | 19,554,100) | 22,929,400) | 22,231,800) | 24,002,000) | 25,936,400) | 25,843,500) | 26,539,100) | 26,443,300) | 26,223,000) | 29,970,800) | 31,178,200) | 37,075,100) | 38,551,800) | 40,293,400) | 40,648,100) | 41,319,400) | 42,700,500) | |||||||
| Total debt | 19,549,700) | 22,649,000) | 22,525,200) | 22,703,500) | 23,525,900) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Total assets | 88,426,200) | 94,699,100) | 94,408,900) | 95,480,700) | 98,036,300) | 101,787,600) | 106,542,500) | 108,858,800) | 112,021,300) | 118,341,900) | 118,992,800) | 124,734,800) | 126,836,900) | 128,986,300) | 143,607,700) | 132,619,100) | 136,073,700) | 135,840,700) | 142,816,300) | 138,411,100) | 139,460,700) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to assets1 | 0.22 | 0.24 | 0.24 | 0.24 | 0.24 | 0.23 | 0.22 | 0.23 | 0.24 | 0.25 | 0.25 | 0.24 | 0.25 | 0.25 | 0.23 | 0.30 | 0.31 | 0.31 | 0.30 | 0.31 | 0.32 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 0.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= 19,549,700 ÷ 88,426,200 = 0.22
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Allergan PLC debt to assets ratio deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
Debt to Assets (including Operating Lease Liability)
Allergan PLC, debt to assets (including operating lease liability) calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current portion of long-term debt | 1,950,700) | 4,532,500) | 3,739,200) | 3,094,200) | 3,971,800) | 868,300) | 1,351,600) | 1,348,500) | 626,200) | 4,231,800) | 3,797,000) | 3,795,000) | 5,526,400) | 2,797,900) | 1,591,800) | 2,506,600) | 4,015,700) | 2,432,800) | 2,035,400) | 1,550,900) | 1,624,100) | |||||||
| Long-term debt, excluding current portion | 17,599,000) | 18,116,500) | 18,786,000) | 19,609,300) | 19,554,100) | 22,929,400) | 22,231,800) | 24,002,000) | 25,936,400) | 25,843,500) | 26,539,100) | 26,443,300) | 26,223,000) | 29,970,800) | 31,178,200) | 37,075,100) | 38,551,800) | 40,293,400) | 40,648,100) | 41,319,400) | 42,700,500) | |||||||
| Total debt | 19,549,700) | 22,649,000) | 22,525,200) | 22,703,500) | 23,525,900) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Current portion of lease liability, operating | 119,800) | 124,400) | 118,400) | 123,200) | 116,100) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Lease liability, operating, excluding current portion | 438,300) | 446,100) | 437,400) | 414,800) | 415,200) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 20,107,800) | 23,219,500) | 23,081,000) | 23,241,500) | 24,057,200) | 23,797,700) | 23,583,400) | 25,350,500) | 26,562,600) | 30,075,300) | 30,336,100) | 30,238,300) | 31,749,400) | 32,768,700) | 32,770,000) | 39,581,700) | 42,567,500) | 42,726,200) | 42,683,500) | 42,870,300) | 44,324,600) | |||||||
| Total assets | 88,426,200) | 94,699,100) | 94,408,900) | 95,480,700) | 98,036,300) | 101,787,600) | 106,542,500) | 108,858,800) | 112,021,300) | 118,341,900) | 118,992,800) | 124,734,800) | 126,836,900) | 128,986,300) | 143,607,700) | 132,619,100) | 136,073,700) | 135,840,700) | 142,816,300) | 138,411,100) | 139,460,700) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | 0.23 | 0.25 | 0.24 | 0.24 | 0.25 | 0.23 | 0.22 | 0.23 | 0.24 | 0.25 | 0.25 | 0.24 | 0.25 | 0.25 | 0.23 | 0.30 | 0.31 | 0.31 | 0.30 | 0.31 | 0.32 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 20,107,800 ÷ 88,426,200 = 0.23
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Allergan PLC debt to assets ratio (including operating lease liability) deteriorated from Q3 2019 to Q4 2019 but then improved from Q4 2019 to Q1 2020 exceeding Q3 2019 level. |
Financial Leverage
Allergan PLC, financial leverage calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Total assets | 88,426,200) | 94,699,100) | 94,408,900) | 95,480,700) | 98,036,300) | 101,787,600) | 106,542,500) | 108,858,800) | 112,021,300) | 118,341,900) | 118,992,800) | 124,734,800) | 126,836,900) | 128,986,300) | 143,607,700) | 132,619,100) | 136,073,700) | 135,840,700) | 142,816,300) | 138,411,100) | 139,460,700) | |||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | 76,591,400) | 77,473,700) | 72,069,100) | 71,404,800) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Financial leverage1 | 1.52 | 1.63 | 1.61 | 1.60 | 1.59 | 1.56 | 1.51 | 1.53 | 1.55 | 1.60 | 1.67 | 1.66 | 1.69 | 1.69 | 1.60 | 1.73 | 1.76 | 1.77 | 1.84 | 1.92 | 1.95 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 6.50 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 2.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 2.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 13.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 2.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 3.24 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 2.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 2.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 1.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 88,426,200 ÷ 57,997,700 = 1.52
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Allergan PLC financial leverage ratio increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020. |
Interest Coverage
Allergan PLC, interest coverage calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Net income (loss) attributable to shareholders | 378,000) | (317,200) | (786,800) | (1,759,000) | (2,408,000) | (4,299,900) | (37,900) | (472,500) | (286,100) | 3,121,300) | (3,955,700) | (725,900) | (2,565,200) | (600) | 15,220,000) | (501,700) | 255,700) | (630,900) | 5,301,200) | (243,100) | (512,000) | |||||||
| Add: Net income attributable to noncontrolling interest | 1,000) | (100) | 1,200) | 4,100) | 700) | 4,000) | 1,600) | 2,400) | 2,200) | 1,900) | 1,700) | 2,000) | 1,000) | 1,800) | 1,800) | 1,800) | 700) | 1,600) | 1,400) | 1,500) | (300) | |||||||
| Less: Income (loss) from discontinued operations, net of tax | —) | —) | —) | —) | —) | —) | —) | —) | —) | (385,300) | (6,100) | (8,400) | (3,100) | 41,300) | 15,601,900) | (77,300) | 348,600) | 355,900) | 6,157,400) | —) | 274,400) | |||||||
| Add: Income tax expense | (1,866,800) | (104,700) | 18,100) | 301,600) | (68,600) | (1,296,700) | 213,400) | (5,200) | (682,200) | (3,918,300) | (1,638,800) | (581,200) | (532,100) | (1,071,200) | (158,900) | (258,200) | (408,700) | (170,700) | (824,900) | (307,300) | (259,000) | |||||||
| Add: Interest expense | 184,500) | 191,900) | 193,900) | 195,400) | 201,800) | 210,200) | 220,400) | 230,000) | 250,600) | 263,300) | 265,200) | 277,400) | 289,700) | 292,700) | 324,300) | 345,800) | 332,800) | 341,300) | 340,200) | 339,900) | 171,900) | |||||||
| Earnings before interest and tax (EBIT) | (1,303,300) | (230,100) | (573,600) | (1,257,900) | (2,274,100) | (5,382,400) | 397,500) | (245,300) | (715,500) | (146,500) | (5,321,500) | (1,019,300) | (2,803,500) | (818,600) | (214,700) | (335,000) | (168,100) | (814,600) | (1,339,500) | (209,000) | (873,800) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Interest coverage1 | -4.39 | -5.54 | -11.84 | -10.29 | -8.70 | -6.53 | -0.74 | -6.37 | -6.82 | -8.48 | -8.86 | -4.10 | -3.33 | -1.19 | -1.14 | -1.95 | -1.87 | -2.71 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Interest coverage
= (EBITQ1 2020
+ EBITQ4 2019
+ EBITQ3 2019
+ EBITQ2 2019)
÷ (Interest expenseQ1 2020
+ Interest expenseQ4 2019
+ Interest expenseQ3 2019
+ Interest expenseQ2 2019)
= (-1,303,300 + -230,100 + -573,600 + -1,257,900)
÷ (184,500 + 191,900 + 193,900 + 195,400)
= -4.39
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Allergan PLC interest coverage ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |